Literature DB >> 8452372

In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.

G M Eliopoulos1, K Klimm, C T Eliopoulos, M J Ferraro, R C Moellering.   

Abstract

The in vitro activity of the fluoroquinolone CP-99,219 against gram-positive bacteria was compared with those of five other antimicrobial agents. Against ciprofloxacin-susceptible staphylococci and against streptococci, MICs were < or = 0.12 and < or = 0.5 microgram/ml, respectively. CP-99,219 was also more active than ciprofloxacin against ciprofloxacin-resistant staphylococci, most enterococci, Leuconostoc spp., and lactobacilli.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8452372      PMCID： PMC187672          DOI： 10.1128/AAC.37.2.366

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.

Authors:  P C Fuchs; A L Barry; M A Pfaller; S D Allen; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

2.  Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agent.

Authors:  G M Eliopoulos; K Klimm; L B Rice; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  In-vitro activity of Sch 29482 in comparison with other oral antibiotics.

Authors:  G M Eliopoulos; A Gardella; R C Moellering
Journal:  J Antimicrob Chemother       Date:  1982-02       Impact factor: 5.790

4.  Rapid dissemination of beta-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward.

Authors:  E Rhinehart; N E Smith; C Wennersten; E Gorss; J Freeman; G M Eliopoulos; R C Moellering; D A Goldmann
Journal:  N Engl J Med       Date:  1990-12-27       Impact factor: 91.245

5.  Comparison of Enterococcus raffinosus with Enterococcus avium on the basis of penicillin susceptibility, penicillin-binding protein analysis, and high-level aminoglycoside resistance.

Authors:  M L Grayson; G M Eliopoulos; C B Wennersten; K L Ruoff; K Klimm; F L Sapico; A S Bayer; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

6.  Transferable beta-lactamase. A new mechanism for in vitro penicillin resistance in Streptococcus faecalis.

Authors:  B E Murray; B Mederski-Samaroj
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

7.  Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocci.

Authors:  A G Miranda; A R Wanger; K V Singh; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191
  7 in total
  53 in total

1.  Trovafloxacin in combination with vancomycin against penicillin-resistant pneumococci in the rabbit meningitis model.

Authors:  D Rodoni; F Hänni; C M Gerber; M Cottagnoud; K Neftel; M G Täuber; P Cottagnoud
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

2.  In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone.

Authors:  M Takahata; J Mitsuyama; Y Yamashiro; M Yonezawa; H Araki; Y Todo; S Minami; Y Watanabe; H Narita
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 3.  Trovafloxacin.

Authors:  M Haria; H M Lamb
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

4.  Activity of newer fluoroquinolones in vitro against gram-positive bacteria.

Authors:  G M Eliopoulos
Journal:  Drugs       Date:  1999       Impact factor: 9.546

5.  Effect of ethanol on fluoroquinolone efficacy in a rat model of pneumococcal pneumonia.

Authors:  Keith M Olsen; Martha Gentry-Nielsen; Mei Yue; Mary U Snitily; Laurel C Preheim
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

6.  In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.

Authors:  E J Giamarellos-Bourboulis; H Sambatakou; P Grecka; H Giamarellou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-09       Impact factor: 3.267

7.  Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

8.  In vitro activity of the new fluoroquinolone CP-99,219.

Authors:  H C Neu; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

9.  Postantibiotic effect of trovafloxacin against gram-positive and -negative organisms.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

10.  In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms.

Authors:  L A Collins; G M Eliopoulos; C B Wennersten; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.